Pharmacological treatment. Psychopharmacs;Tratamiento farmacológico. Psicofármacos

Adicciones

Volumn 16, Issue SUPPL. 2, 2004, Pages 275-285

  Sáiz Martínez, Pilar Alejandra ^a   García Portilla González, Ma Paz ^a   Martínez Barrondo, Sara ^a   Bascarán Fernández, Ma Teresa ^a   Paredes Ojanguren, Begoña ^a   Bobes García, Julio ^a,b  

^a UNIVERSIDAD DE OVIEDO   (Spain)

^b Faculty de Medicina   (Spain)

Author keywords

Bupropion; Nicotine dependence; Pharmacological approach; Relapse prevention

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CLONIDINE; DOPAMINE; MECAMYLAMINE; NALTREXONE; NICOTINE; NORADRENALIN; RIMONABANT; SELEGILINE; SEROTONIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADDICTION; CIGARETTE SMOKING; DRUG EFFECT; DRUG EFFICACY; HUMAN; NEUROTRANSMITTER RELEASE; NICOTINE REPLACEMENT THERAPY; PASSIVE IMMUNIZATION; RELAPSE; REVIEW; SMOKING CESSATION; WITHDRAWAL SYNDROME;

EID: 3242671702     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. American Psychiatric Association. DSM-IV-TR. Manual diagnóstico y estadístico de los trastornos mentales. Barcelona: Masson, 2002.
2. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
3. Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract 2001; 55: 53-57.
4. Becoña E. Guía clínica para ayudar a los fumadores a dejar de fumar. Palma de Mallorca: Socidrogalcohol, 2004.
5. Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58: 444-452.
6. Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation - a randomized trial. Addiction 1999; 94: 1007-1015.
7. Carrera MR, Ashley JA, Hoffman TZ, Isomura S, Wirsching P, Koob GF et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 2004; 12: 563-570.
8. Carreras JM, Quesada M, Maldonado B, Sánchez-Agudo L. Terapia sustitutiva con nicotina en el tratamiento actual del tabaquismo. Prevención del Tabaquismo 2003; 5: 19-28.
9. Cinciripini PM, Lapitsky L, Seay S, Wallfisch A, Meyer WJ 3rd, van Vunakis H. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high- and low-anxiety smokers. J Clin Psychopharmacol 1995; 15: 182-191.
10. Cinciripini PM, McClure JB. Smoking cessation: recent developments in behavioral and pharmacologic interventions. Oncology 1998; 12: 249-270.
11. Clarke PB. Nicotinic receptor blockade therapy and smoking cessation. Br J Addict 1991; 86: 501-505.
12. Covey LS, Glassman AH. A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. Br J Addict 1991; 86: 991-998.
13. Cryan JF, Gasparini F, van Heeke G, Markou A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today 2003; 8: 1025-1034.
14. Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psychiatry 1989; 146: 373-376.
15. Fiore MC, Bailay WC, Cohen SJ. Treating tobacco use and dependence. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service, June 2000.
16. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003; 53: 136-143.
17. George TP, O'Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004; 25: 42-48.
18. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB et al. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 1988; 259: 2863-2866.
19. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, Fleiss J et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993; 54: 670-679.
20. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995; 50: 197-207.
21. Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683-690.
22. Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59: 930-936.
23. Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174: 173-178.
24. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001; 135: 423-433.
25. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs 2000; 59: 1007-1024.
26. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37: 737-743.
27. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-1202.
28. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691.
29. Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M et al. Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol 2000; 68: 883-889.
30. Kotlyar M, Golding M, Hatsukami DK, Jamerson BD. Effect of nonnicotine pharmacotherapy on smoking behavior. Pharmacotherapy 2001; 21: 1530-1548.
31. Krishnan-Sarin S, Meandzija B, O'Malley S. Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tob Res 2003; 5: 851-857.
32. Lorenzo P, Ladero JM. Dependencia tabáquica. Tabaco y nicotina. En: Lorenzo P, Ladero JM, Leza JC, Lizasoian I (eds.). Drogodependencias. Farmacología. Patología. Psicología. Legislación. Madrid: Ed. Médica Panamericana, 2003.
33. Malin DH, Lake JR, Lin A, Saldana M, Balch L, Irvin ML et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001; 68: 87-92.
34. Markou A, Kenny PJ. Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotox Res 2002; 4: 297-313.
35. McRobbie H, Aaserud E, Lefrandt JD. Bupropion SR (Zyban) is an effective and well-tolerated aid to smoking cessation in smokers with cardiovascular disease: an international study. Paper presented at the SRNT Meeting. Paris, Septiembre, 2001.
36. Murray RP, Voelker HT, Rakos RF, Nides MA, McCutcheon VJ, Bjornson W. Intervention for relapse to smoking: the Lung Health Study restart programs. Addict Behav 1997; 22: 281-286.
37. Nana A, Praditsuwan R. Clonidine for smoking cessation. J Med Assoc Thai 1998; 81: 87-93.
38. National Institute for Clinical Excellence (NICE). Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Technology Appraisal Guidance, n° 39. London, 2002.
39. Niaura R, Brown RA, Goldstein MG, Murphy JK, Abrams DB. Transdermal clonidine for smoking cessation: a double-blind randomized dose-response study. Exp Clin Psychopharmacol 1996; 4: 285-291.
40. Niaura R, Spring B, Borrelli B, Hedeker D, Goldstein MG, Keuthen N et al. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 2002; 70: 887-896.
41. Pinet C. Tratamiento del tabaquismo. En: Bobes J, Casas M, Gutiérrez M (eds.). Manual de evaluación y tratamiento de drogodependencias. Barcelona: Ars Medica, 2003.
42. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 2035-2039.
43. Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ 2004; 328: 509-511.
44. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994; 56: 86-99.
45. Rose JE, Behm FM, Westman EC. Nicotinemecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 1998; 6: 331-343.
46. Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation. Database of abstracts of reviews of effectiveness. En: Cochrane Library, Issue 2. Oxford: Update Software, 1998.
47. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321-327.
48. Sociedad Española de Neumología y Cirugía Torácica. Manuales SEPAR, Tabaquismo. Volumen 1. Madrid: SEPAR, 1995.
49. Sociedad Española de Psiquiatría. Consenso de la Sociedad Española de Psiquiatría sobre diagnóstico y tratamiento del alcoholismo y otras adicciones. Barcelona: Euromedice, 2003.
50. Stolerman IP, Goldfarb T, Fink R, Jarvik ME. Influencing cigarette smoking with nicotine antagonists. Psychopharmacologia 1973; 28: 247-259.
51. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.
52. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction 1999; 94: 1227-1237.